David C Hastings - Net Worth and Insider Trading

David C Hastings Net Worth

The estimated net worth of David C Hastings is at least $934,496 dollars as of 2024-04-26. David C Hastings is the CFO of Arbutus Biopharma Corp and owns about 181,907 shares of Arbutus Biopharma Corp (ABUS) stock worth over $494,787. David C Hastings is the CFO of Incyte Corp and owns about 8,500 shares of Incyte Corp (INCY) stock worth over $435,030. David C Hastings is also the Director of SCYNEXIS Inc and owns about 3,183 shares of SCYNEXIS Inc (SCYX) stock worth over $4,679. Details can be seen in David C Hastings's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that David C Hastings has not made any transactions after 2024-02-02 and currently still holds the listed stock(s).

Transaction Summary of David C Hastings

To

David C Hastings Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, David C Hastings owns 6 companies in total, including SCYNEXIS Inc (SCYX) , Entasis Therapeutics Holdings Inc (ETTX) , and Arbutus Biopharma Corp (ABUS) among others .

Click here to see the complete history of David C Hastings’s form 4 insider trades.

Insider Ownership Summary of David C Hastings

Ticker Comapny Transaction Date Type of Owner
SCYX SCYNEXIS Inc 2023-06-15 director
ETTX Entasis Therapeutics Holdings Inc 2019-06-19 director
ABUS Arbutus Biopharma Corp 2024-02-02 Chief Financial Officer
UNISQ Unilife Corp 2017-01-26 See Remarks
INCY Incyte Corp 2014-06-05 Exec VP & CFO
VBLT Vascular Biogenics Ltd 2023-01-01 director

David C Hastings Latest Holdings Summary

David C Hastings currently owns a total of 3 stocks. Among these stocks, David C Hastings owns 181,907 shares of Arbutus Biopharma Corp (ABUS) as of February 2, 2024, with a value of $494,787 and a weighting of 52.95%. David C Hastings owns 8,500 shares of Incyte Corp (INCY) as of June 5, 2014, with a value of $435,030 and a weighting of 46.55%. David C Hastings also owns 3,183 shares of SCYNEXIS Inc (SCYX) as of March 8, 2018, with a value of $4,679 and a weighting of 0.5%.

Latest Holdings of David C Hastings

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ABUS Arbutus Biopharma Corp 2024-02-02 181,907 2.72 494,787
INCY Incyte Corp 2014-06-05 8,500 51.18 435,030
SCYX SCYNEXIS Inc 2018-03-08 3,183 1.47 4,679

Holding Weightings of David C Hastings


David C Hastings Form 4 Trading Tracker

According to the SEC Form 4 filings, David C Hastings has made a total of 1 transactions in Arbutus Biopharma Corp (ABUS) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Arbutus Biopharma Corp is the sale of 9,593 shares on February 2, 2024, which brought David C Hastings around $22,160.

According to the SEC Form 4 filings, David C Hastings has made a total of 0 transactions in Incyte Corp (INCY) over the past 5 years. The most-recent trade in Incyte Corp is the sale of 200,000 shares on June 5, 2014, which brought David C Hastings around $11 Million.

According to the SEC Form 4 filings, David C Hastings has made a total of 0 transactions in SCYNEXIS Inc (SCYX) over the past 5 years. The most-recent trade in SCYNEXIS Inc is the acquisition of 1,183 shares on March 8, 2018, which cost David C Hastings around $20,000.

Insider Trading History of David C Hastings

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

David C Hastings Trading Performance

GuruFocus tracks the stock performance after each of David C Hastings's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David C Hastings is 27.38%. GuruFocus also compares David C Hastings's trading performance to market benchmark return within the same time period. The performance of stocks bought by David C Hastings within 3 months outperforms 5 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how David C Hastings's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of David C Hastings

Average Return

70.06%

Average return per transaction

Outperforming Transactions

60%

3 out of 5 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 16.14 27.38 22.07 70.06 48.46 9.6
Relative Return to S&P 500(%) 11.67 24.17 9.88 50.31 36.83 1.58

David C Hastings Ownership Network

Ownership Network List of David C Hastings

No Data

Ownership Network Relation of David C Hastings


David C Hastings Owned Company Details

What does SCYNEXIS Inc do?

Who are the key executives at SCYNEXIS Inc?

David C Hastings is the director of SCYNEXIS Inc. Other key executives at SCYNEXIS Inc include Chief Financial Officer Ivor Macleod , General Counsel Scott Sukenick , and Interim CFO Lawrence R Hoffman .

SCYNEXIS Inc (SCYX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of SCYNEXIS Inc (SCYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of SCYNEXIS Inc (SCYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

SCYNEXIS Inc (SCYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

SCYNEXIS Inc Insider Transactions

No Available Data

David C Hastings Mailing Address

Above is the net worth, insider trading, and ownership report for David C Hastings. You might contact David C Hastings via mailing address: C/o Arbutus Biopharma, 100-8900 Glenlyon Parkway, Burnaby A1 V5j 5j8.

Discussions on David C Hastings

No discussions yet.